Skin Elements (ASX:SKN) Enters Trading Halt Pending a Capital Raise Announcement

Sonal Goyal

23 October 2026 01:27 AM AEDT

Skin Elements (ASX:SKN) Enters Trading Halt Pending a Capital Raise Announcement

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Skin Elements requested a trading halt with immediate effect on 23 October 2026.
The halt is pending an announcement by the company of a capital raise.
Trading is set to remain halted until the earlier of an announcement or the start of normal trading on Tuesday 27 October 2026.
The company said it is not aware of any other information needed to inform the market about the halt.

Skin Elements Limited (ASX:SKN) asked ASX on 23 October 2026 to place its securities in a trading halt. ASX Supervision published a market announcement the same day confirming that trading in SKN securities would be halted at the company's request, pending the release of an announcement. The company's request letter states that the announcement relates to a capital raise.

Details of the Halt Request

In its letter to ASX in Perth, Skin Elements asked for the halt to take effect immediately. The request was made under ASX Listing Rule 17.1, which requires a company to give the exchange certain information when seeking a halt. The company asked for the halt to continue until the earlier of the making of an announcement or the commencement of trading on Tuesday 27 October 2026.

Skin Elements also confirmed that it is not aware of any other information necessary to inform the market about the trading halt, and that it knows of no reason why the halt should not be granted. The letter was authorised for release by the Board of Skin Elements Limited.

What a Trading Halt Means

While a security is in a trading halt, it cannot be bought or sold on the ASX market. ASX said that unless it decides otherwise, SKN securities will stay in the halt until the earlier of the start of normal trading on 27 October 2026 or the release of the announcement to the market. Because the letter refers to a capital raise, the terms of any raising, including its size, pricing and structure, were not disclosed in the documents released on 23 October 2026.

About Skin Elements

Skin Elements describes itself as an Australian-owned and operated natural biotechnology company focused on developing its SE Formula biotechnology. The company says its research into plant-based and organic ingredients has produced a portfolio of all-natural plant-based formulations with global applications. Products named in the letter include SuprCuvr, which is listed on the ARTG, a hospital-grade plant-based disinfectant, the ECO-Nurture plant bio-stimulant, Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare products and the Elizabeth Jane Natural Cosmetics brand.

Why This Could Matter

A trading halt pending a capital raise generally signals that the company expects to release market-sensitive information that it wants to disclose to all investors at the same time. For Skin Elements shareholders, the immediate effect is that SKN securities cannot trade until the halt ends. The substance of the announcement, including how much the company intends to raise and what it plans to do with the money, remains unknown until it is released.

Where Things Stand

SKN securities are in a trading halt that ends no later than the start of trading on Tuesday 27 October 2026. The capital raise announcement is the next item to watch, and its release would end the halt earlier.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.